Antidepressant use may contribute to long-term population weight gain

Researchers at King's College London have found that patients prescribed any of the 12 most commonly used antidepressants were 21% more likely to experience an episode of gain weight than those not taking the drugs, (after adjusting for other factors which might affect this result). The full research is published in the BMJ.

They also found that the increased relative risk of weight gain hits its peak after two to three years of continued use and that for patients classified as being of 'normal' weight, the risk of moving to either the overweight or obese categories increased by 29%, compared to those not taking antidepressants.

For patients in the overweight category, the risk of transitioning to the obese category was also 29% higher for those prescribed antidepressants than those not on the drugs.

While previous studies have identified short-term weight gain following the start of antidepressant treatment, this study reveals that the risk of weight gain is elevated and sustained for multiple years after the start of treatment. The King's team analysed the electronic health records of just under 300,000 UK patients - 136,762 men and 157,957 women, from 2004 to 2014.

The group was analysed according to whether or not they had been prescribed an antidepressant in a given year and was made up of patients from all weight categories - from normal with a BMI ranging from 18.5 to 14.9, to super obese - with a BMI of 45.0 or greater*. v During the ten-year follow-up period, any recorded increase in body weight of at least 5% was identified. Because patients took antidepressants intermittently throughout the ten years, researchers assessed the actual time they were at risk in order to calculate the annual risk for the entire cohort.

Weight gain was calculated as an increase of 5% of baseline weight; this equates to approximately half a stone for a 70kg person. Researchers also found that that the annual risk of this weight increase was 8.1 per 100 for the group not taking antidepressants, but 11.2 per 100 for those taking antidepressants.

During the second and third years of treatment (the peak risk period) the chance of a 5% body weight gain for those on antidepressants was at least 46% higher than in the group not taking antidepressants. The risk of weight gain remained elevated for up to six years.

Speaking about the research, lead author Dr Rafael Gafoor from King's College London, said: "Our results show that antidepressant treatment increases the risk of patients gaining weight over a period of years. From a clinical perspective, these observations reinforce the need for active, tailored and sustained body weight management to go hand in hand with the prescribing of antidepressant treatments.

"It's important to stress that no patients should stop taking their medication and that if they have any concerns they should speak with their doctor or pharmacist."

Co-author, Professor of Public Health at King's College London, Martin Gulliford, said "The increasingly widespread use of antidepressants may be contributing to long-term population weight gain with associated health risks.

"These results should be set in the context of increasing body mass index in the general population. Data from the Health Survey of England shows that between 2004 and 2014 the prevalence of obesity increased from 23% to 26%."

Rafael Gafoor, Helen P Booth, Martin C Gulliford.
Antidepressant utilisation and incidence of weight gain during 10 years' follow-up: population based cohort study.
BMJ 2018; 361: k1951. doi: 10.1136/bmj.k1951.

Most Popular Now

Top 20 breaking World Pharma News of 2018

World Pharma News proudly presents the top 20 most popular breaking news from 2018. Have a wonderful 2019 New(s) Year filled with health, happiness, and spectacular succe...

FDA approves first treatment for rare blood diseas…

The U.S. Food and Drug Administration today approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adu...

Bristol-Myers Squibb to acquire Celgene to create …

Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG) today announced that they have entered into a definitive merger agreement under which Bristo...

Lynparza meets primary endpoint in Phase III SOLO-…

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced positive results from the randomised, open-label, contro...

Pediatric leukemia 'super drug' could be developed…

Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published ...

Researchers uncover new mechanism of gene regulati…

Genes contain all the information needed for the functioning of cells, tissues, and organs in our body. Gene expression, meaning when and how are the genes being read and...

Tumors backfire on chemotherapy

Some patients with breast cancer receive chemotherapy before the tumor is removed with surgery. This approach, called 'neoadjuvant' therapy, helps to reduce the size of t...

AstraZeneca announces organisational changes

AstraZeneca is today announcing organisational changes to support continued scientific innovation and commercial success in the main therapy areas as the Company enters a...

Sandoz and Pear Therapeutics announce US launch of…

Sandoz Inc., a Novartis division, and Pear Therapeutics, Inc., announced today the US commercial launch of reSET-O(TM) for patients with Opioid Use Disorder (OUD). reSET-...

Stopping cancer from recruiting immune system doub…

Cancerous tumors trick myeloid cells, an important part of the immune system, into perceiving them as a damaged part of the body; the tumors actually put myeloid cells to...

Boehringer Ingelheim initiates a collaborative par…

Science 37, an industry leader in virtual clinical trials, and Boehringer Ingelheim announced a technology enterprise collaboration agreement that will support Boehringer...

Pfizer initiates phase 2b/3 clinical trial for PF-…

Pfizer Inc. (NYSE: PFE) announced the initiation of a Phase 2b/3 clinical trial for its oral JAK3 inhibitor, PF-06651600, for the treatment of patients with moderate to s...